Berberine improves lipid levels, vascular function, and gut microbial-dependent metabolites in stable coronary artery disease patients
- 1Department of Cardiology, Peking Union Medical College & Chinese Academy of Medical Sciences , ,
- 2Department of Internal Medicine, Peking Union Medical College & Chinese Academy of Medical Sciences , ,
Abstract
Berberine (BBR) has been demonstrated to exert cardiovascular protective effects by regulating lipids and ameliorating inflammation. Recent studies reported the interaction between BBR and gut microbiota in various metabolic diseases due to its low bioavailability. However, few studies examine the effect of BBR on the gut microbiota in coronary artery disease (CAD) individuals. We hence conducted a parallel-controlled, regularly visited clinical trial with 23 stable CAD patients who recently underwent percutaneous coronary intervention and completed a 12-week BBR ± standard therapy treatment. The BBR intervention was associated with a directional improvement in endothelial function, enhanced levels of low-density lipoprotein cholesterol (LDL-C), and a reduction in circulating inflammatory mediators (IL-1α, IL-17, MCP-1, MIP-1β, and VEGF). Using metagenomics and metabolomic studies, we identified that bacterial signatures varied significantly with gradually increasing doses of BBR. These results showed that a specific group of short-chain fatty acid (SCFA)-producing bacteria, mainly Ruminococcus sp., Roseburia sp., and Anaerostipes hadrus, were elevated following the BBR intervention, which was also negatively correlated with inflammatory factors. Notably, regardless of the background standard therapy, BBR reshaped gut-microbiota–encoded aromatic amino acid catabolism: it selectively enriched the microbial L-dopa, 3-hydroxyphenylacetic acid, and phenylpropionic acid branches, which were anchored by increased abundances of dopamine β-monooxygenase, porA, and acdA genes. Overall, we investigated the role of BBR in regulating microbial metabolic alterations and vascular function. Targeted restoration of the gut microbiota may present a novel ecological approach for managing cardiovascular disease.
Related
- Intratracheal Administration of Benzbromarone Attenuates Pulmonary Vascular Remodeling and Improves Survival in Rats with Monocrotaline-Induced Pulmonary Hypertension
- Expression of Versican Isoform V3 in the Absence of Ascorbate Improves Elastogenesis in Engineered Vascular Constructs
- Microbial metabolites in chemotherapy-induced cognitive impairment: from mechanistic associations to pharmacological target validation
- From Tea Catechins to Microbial Metabolites: Emerging Mechanisms for Modulating Gut-Origin α-Synuclein Seeding in Parkinson’s Disease
- Eight-week flexi-bar vibration exercise improves cardiovascular function accompanied by altered gut microbiota and metabolites in middle-aged and elderly women: a randomized controlled trial
BibTeX
@article{liu2026berberine,
title = {{Berberine improves lipid levels, vascular function, and gut microbial-dependent metabolites in stable coronary artery disease patients}},
author = {Honghong Liu and Siqin Feng and Muyun Tang and Jiejun Sun and Ran Tian and Shuyang Zhang},
journal = {Frontiers in nutrition},
year = {2026},
month = oct,
doi = {10.3389/fnut.2026.1945710},
url = {https://europepmc.org/article/PMC/PMC13727732},
note = {CC BY},
}
RIS
TY - JOUR
TI - Berberine improves lipid levels, vascular function, and gut microbial-dependent metabolites in stable coronary artery disease patients
AU - Honghong Liu
AU - Siqin Feng
AU - Muyun Tang
AU - Jiejun Sun
AU - Ran Tian
AU - Shuyang Zhang
PY - 2026
DA - 2026/10/20
JO - Frontiers in nutrition
DO - 10.3389/fnut.2026.1945710
UR - https://europepmc.org/article/PMC/PMC13727732
AB - Berberine (BBR) has been demonstrated to exert cardiovascular protective effects by regulating lipids and ameliorating inflammation. Recent studies reported the interaction between BBR and gut microbiota in various metabolic diseases due to its low bioavailability. However, few studies examine the effect of BBR on the gut microbiota in coronary artery disease (CAD) individuals. We hence conducted a parallel-controlled, regularly visited clinical trial with 23 stable CAD patients who recently underwent percutaneous coronary intervention and completed a 12-week BBR ± standard therapy treatment. The BBR intervention was associated with a directional improvement in endothelial function, enhanced levels of low-density lipoprotein cholesterol (LDL-C), and a reduction in circulating inflammatory mediators (IL-1α, IL-17, MCP-1, MIP-1β, and VEGF). Using metagenomics and metabolomic studies, we identified that bacterial signatures varied significantly with gradually increasing doses of BBR. These results showed that a specific group of short-chain fatty acid (SCFA)-producing bacteria, mainly Ruminococcus sp., Roseburia sp., and Anaerostipes hadrus, were elevated following the BBR intervention, which was also negatively correlated with inflammatory factors. Notably, regardless of the background standard therapy, BBR reshaped gut-microbiota–encoded aromatic amino acid catabolism: it selectively enriched the microbial L-dopa, 3-hydroxyphenylacetic acid, and phenylpropionic acid branches, which were anchored by increased abundances of dopamine β-monooxygenase, porA, and acdA genes. Overall, we investigated the role of BBR in regulating microbial metabolic alterations and vascular function. Targeted restoration of the gut microbiota may present a novel ecological approach for managing cardiovascular disease.
SN - 2296-861X
ER -